Is the New mRNA Flu Jab Better? What the 40,000-Person Trial Found

Yes, in the largest head-to-head test so far, the new mRNA flu vaccine prevented roughly a quarter more lab-confirmed flu cases than the standard jab. The US Food and Drug Administration approved it on 5 August 2026 for adults aged 50 and over, making it the first mRNA-based flu vaccine ever licensed. It is not a universal flu vaccine, it is not approved for everyone, and it comes with a sore-arm trade-off. Here is the trial, decoded.

If you are searching for the new flu vaccine 2026, this guide walks through what mFLUSIVA is, exactly what the 40,703-person trial measured, what the 26.6% effectiveness figure really means, and whether it is worth switching this flu season.

What is mFLUSIVA and how is it different from the standard flu jab?

mFLUSIVA (mRNA-1010) is Moderna’s mRNA-based seasonal flu vaccine. The FDA approved it on 5 August 2026 for the prevention of seasonal influenza in adults aged 50 and older, which makes it the first flu vaccine built on mRNA technology to reach the US market. Moderna described it as the company’s fourth approved product in the United States.

The difference from the jab you have had every year comes down to manufacturing. Standard flu vaccines are grown in fertilised chicken eggs, a process that takes roughly six months from strain selection to distribution. mFLUSIVA is manufactured from genetic sequences encoding the haemagglutinin protein of three influenza strains (H1N1, H3N2 and B/Victoria), encapsulated in lipid nanoparticles. The manufacturing process takes roughly two to three months from strain selection.

Two details matter for understanding the trial results. First, because the virus is never grown in eggs, the vaccine avoids the egg-adaptation mutations that can weaken how well a standard vaccine matches circulating flu strains. Second, it does not contain live or inactivated flu virus, so it cannot give you influenza. The documented trade-off, which we will come to, is reactogenicity: more sore arms and more short-lived systemic symptoms than the standard jab.

What did the 40,000-person trial actually test?

The headline numbers come from a phase 3, double-blind, active-controlled trial published in the New England Journal of Medicine on 7 May 2026. Adults aged 50 or older were randomly assigned to receive either trivalent mRNA-1010 (37.5 micrograms, comprising 12.5 micrograms of each WHO-recommended influenza strain) or a licensed standard-dose comparator. In total, 20,350 participants received mRNA-1010 and 20,353 received the standard-dose vaccine, across 11 countries.

The primary endpoint was RT-PCR-confirmed, protocol-defined influenza-like illness caused by influenza A or B, measured from at least 14 days after vaccination through the end of the influenza season. In plain terms: the trial asked whether people who got the mRNA jab were less likely to catch lab-confirmed flu than people who got the standard jab. The lead author was Isabel Leroux-Roels of Ghent University and Ghent University Hospital in Belgium.

How much better was it? Decoding the 26.6% number

In the mRNA-1010 group, 411 participants (2.0%) developed RT-PCR-confirmed influenza. In the standard-dose group, 557 (2.8%) did. That translated into a relative vaccine efficacy of 26.6% (95% confidence interval 16.7 to 35.4), and the trial met the pre-specified criteria for noninferiority, superiority and higher-level superiority.

Here is how to read that number correctly, because it is the most misunderstood figure in this story:

• 26.6% is relative, not absolute. It means that among people already receiving a flu jab, the mRNA version cut the remaining risk of confirmed flu by about a quarter. It does not mean only 26.6% of recipients were protected.
• The absolute difference was small but real. A reanalysis of the FDA clinical data put the number needed to vaccinate at 137 to prevent one confirmed illness, and roughly 5,017 to prevent one hospitalisation.
• Both groups were vaccinated. There was no placebo arm, so this trial measures how much better the new jab is than the old one, not how much better it is than nothing.

Researchers who were not involved in the trial described the result as an important proof of concept: it was already known that mRNA flu vaccines generate strong immune responses, and this study showed those responses translate into a meaningful improvement in protection against actual flu illness.

Why did the FDA approve it in two different ways for two age groups?

This is the detail most news coverage glosses over, and it matters if you are 65 or older. The FDA used two different approval pathways, as reported by Pharmacy Times:

• Ages 50 to 64: traditional approval, based on the phase 3 trial’s clinical efficacy data described above.
• Ages 65 and older: accelerated approval, based largely on immune-response data from a separate trial of 2,992 US participants that compared antibody responses against Fluzone High-Dose, rather than on directly measured prevention of illness. Confirmation of clinical benefit in this age group depends on a postmarketing trial Moderna agreed to run.

The regulatory road was bumpy. The FDA initially refused to file the application over questions about the trial’s comparator choice, then reversed course in February 2026. In June 2026, the FDA’s Vaccines and Related Biological Products Advisory Committee unanimously recommended approval, with FDA staff telling the committee the vaccine was about 27% more effective than a standard flu shot in the late-stage trial.

What are the downsides? The honest trade-offs

A studies-decoded piece would not be honest without the caveats:

• More side effects. Every solicited adverse reaction was more frequent with mFLUSIVA than with the standard-dose comparator. Injection-site pain was reported by 65.8% of mRNA recipients versus 29.8% for the standard jab; fatigue by 45.1% and headache by 37.8%. The events were predominantly mild to moderate and resolved within one to two days. Overall, 75.7% of mFLUSIVA recipients reported a solicited reaction versus 46.7% of comparator recipients.
• Serious adverse events were similar: 2.2% with mRNA-1010 versus 1.9% with the standard vaccine, and regulators reported no new safety concerns.
• It was never tested against high-dose jabs. The phase 3 comparator was a standard-dose vaccine, not the high-dose formulation often recommended for older adults. For the over-65s, where high-dose jabs are the usual standard of care, that is a genuine gap the postmarketing study is meant to fill.
• No flu-mortality endpoint. The trial measured confirmed illness, not deaths from influenza.

Who can get it, and when is it available?

The approval covers adults aged 50 and older in the United States. Moderna said it expects mFLUSIVA to be available in select retailers in the coming weeks for the 2026-27 respiratory virus season, alongside its COVID-19 and RSV vaccines. The vaccine has been accepted for regulatory review in the European Union, Canada and Australia, with further submissions planned.

If you are under 50, this approval does not cover you yet. If you are 50 or over, availability and insurance coverage may lag the FDA decision, so check with your pharmacy rather than assuming it is on the shelf. A patient-facing explainer at The Educated Patient has a useful checklist of what to ask about availability and cost.

Should you switch to the new jab this flu season?

Here is the decoded verdict:

If you are 50 or over and offered mFLUSIVA, the trial data support it being meaningfully better than the standard jab at preventing lab-confirmed flu. Expect a sorer arm and a higher chance of a day of fatigue or headache. If you are 65 or over, know that the clinical benefit in your age group rests on immune-response data for now, with a confirmatory trial still to come.

Do not delay vaccination while waiting for it. Flu season does not wait for supply chains, and any licensed flu jab protects far better than none. People with long-term conditions that raise the risk of flu complications, such as diabetes (see our piece on whether prediabetes can be reversed) or high blood pressure (see what 1.4 million health records revealed about hypertension), should get whichever jab is available first and discuss the mRNA option with their clinician or pharmacist.

And if you are in the over-50s audience this vaccine was built for, it is a good moment to check your own numbers with our free calculators. This article is educational, not medical advice: a conversation with your clinician beats any explainer.

Frequently asked questions about the new flu vaccine 2026

How effective is the new mRNA flu vaccine?

In the phase 3 trial of 40,703 adults aged 50 and over, mRNA-1010 showed 26.6% relative vaccine efficacy against lab-confirmed flu compared with a standard-dose jab: 2.0% of mRNA recipients versus 2.8% of standard-dose recipients developed confirmed influenza.

Who can get the new flu vaccine in 2026?

The FDA approved mFLUSIVA for adults aged 50 and older in the United States. Adults 50 to 64 received traditional approval based on clinical efficacy; adults 65 and older received accelerated approval based on immune-response data, with a confirmatory trial required.

What are the side effects of the mRNA flu jab?

Side effects were more common than with the standard jab but mostly mild to moderate and short-lived: injection-site pain in 65.8%, fatigue in 45.1% and headache in 37.8% of recipients, typically resolving within one to two days. Serious adverse events were similar between the two groups (2.2% versus 1.9%).

Is the mRNA flu vaccine available this flu season?

Moderna said it expects mFLUSIVA to be available in select US retailers for the 2026-27 respiratory virus season. Availability and insurance coverage may lag the FDA approval, so check with your pharmacy.

Does the mRNA flu vaccine contain live virus?

No. mFLUSIVA contains mRNA instructions for making the flu haemagglutinin protein, not live or inactivated flu virus, so it cannot give you influenza.